Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Key Inclusion Criteria: * Has a diagnosis of Nontuberculous Mycobacterial pulmonary disease caused by MABc * Has at least 2 of the following NTM-infection symptoms present at Screening and Baseline: chronic cough, coughing up blood (hemoptysis), wheezing, chest pain, frequent throat clearing, phlegm or sputum production, shortness of breath, fatigue, fever, night sweats, poor appetite, and/or weight loss. * At least 1 positive pulmonary (sputum) culture for MABc in the 6 months prior to Screening and 1 positive culture at Screening * Radiographic evidence of MABc infection via computed tomography (CT) scan of the chest within 3 months prior to Screening * In the opinion of the investigator, guideline-directed antibiotic therapy for treatment of MABc will not be required within the next 3 months, and a delay, in order for the subject to participate in a placebo-controlled clinical trial, is considered reasonable and clinically acceptable * Additional inclusion criteria as per protocol Key Exclusion Criteria: * Has received antibiotic treatment within 6 months prior to Screening for MABc or MAC * Has received systemic or inhaled antibiotic therapy (other than chronic macrolide therapy) within 4 weeks prior to Screening * Has any of the following medical conditions: * Active pulmonary malignancy, or any type of malignancy requiring chemotherapy or radiation within 1 year prior to Screening * Active allergic bronchopulmonary mycosis, or any other condition requiring chronic tr…